

1 Supplementary Materials for

2

3 **Effect of Lard or Plus Soybean Oil on Blood Pressure and**
4 **Other Cardiometabolic Risk Factors in Healthy Subjects: A**
5 **Randomized Controlled-Feeding Trial**

6

7 Zhiyuan Liu,^{†a} Jihong Yuan,^{†b} Ping Wen,^c Xiaofei Guo,^a Haichao Wen,^a Yanjun Guo^a and Duo
8 Li^{*a,d,e}

9

10 *^aInstitute of Nutrition & Health, Qingdao University, Qingdao, China*

11 *^bNo. 2 Department of Nutrition, Chinese People's Liberation Army General Hospital, Beijing,*
12 *China*

13 *^cSupply Department, Chinese People's Liberation Army General Hospital, Beijing, China*

14 *^dDepartment of Food Science and Nutrition, Zhejiang University, Hangzhou, China*

15 *^eDepartment of Nutrition, Dietetics and Food, Monash University, Melbourne, Australia*

16

17 [†]These authors contributed equally to this paper.

18

19 ***Correspondence to: Prof Duo Li, PhD**

20 Institute of Nutrition & Health,

21 Qingdao University,

22 308 Ningxia Road, Qingdao 266071, China,


23 E-mail:

duoli@qdu.edu.cn;

duoli@zju.edu.cn

24 Figure S1. Mean changes and diet contrast in nitric oxide in male and female participants. Error
25 bars indicate SEM. Data are based on a mixed-model analysis of variance. The *P* value at the
26 upper left indicates the test of whether the change between baseline and intervention period (mean
27 of every 4 weeks) differed significantly between participants assigned to three diet groups. NO,
28 nitric oxide; wk, week.

29 Figure S1



30

31 Table S1. Fatty acid compositions of cooking oils and diets for three groups

| Fatty acid | Three oils | | | Three diets | | |
|-----------------|--------------|--------------|--------------|-------------------|-----------------|--------------|
| | Soybean oil | Blend oil | Lard | Soybean oil group | Blend oil group | Lard group |
| SFA (%) | | | | | | |
| C14:0 | 0.06 (0.01) | 0.69 (0.12) | 1.58 (0.09) | 0.36 (0.10) | 0.75 (0.06) | 1.26 (0.07) |
| C16:0 | 8.58 (0.50) | 16.04 (0.66) | 25.17 (0.34) | 14.90 (1.22) | 19.73 (0.58) | 25.29 (0.38) |
| C17:0 | 0.03 (0.01) | 0.09 (0.01) | 0.14 (0.01) | 0.08 (0.03) | 0.12 (0.03) | 0.15 (0.03) |
| C18:0 | 1.78 (0.28) | 6.10 (0.21) | 11.97 (0.34) | 4.80 (0.88) | 7.69 (0.54) | 10.99 (0.37) |
| C20:0 | 0.13 (0.01) | 0.11 (0.01) | 0.10 (0.01) | 0.19 (0.09) | 0.17 (0.09) | 0.15 (0.09) |
| MUFA (%) | | | | | | |
| C16:1n-7 | 0.30 (0.02) | 1.17 (0.05) | 2.36 (0.19) | 1.36 (0.28) | 1.87 (0.22) | 2.60 (0.15) |
| C18:1n-9 | 21.44 (1.47) | 30.10 (0.99) | 41.65 (0.78) | 28.92 (1.82) | 34.81 (1.06) | 41.87 (0.56) |
| C20:1n-9 | 0.08 (0.00) | 0.29 (0.03) | 0.59 (0.04) | 0.14 (0.05) | 0.28 (0.05) | 0.45 (0.06) |
| PUFA (%) | | | | | | |
| n-6 PUFA | | | | | | |
| C18:2n-6 | 59.16 (1.88) | 40.50 (1.61) | 14.87 (0.21) | 42.87 (3.72) | 30.35 (2.03) | 15.31 (0.87) |
| C20:2n-6 | | 0.22 (0.02) | 0.50 (0.03) | 0.07 (0.05) | 0.21 (0.04) | 0.38 (0.05) |
| C20:3n-6 | | 0.02 (0.00) | 0.04 (0.00) | 0.03 (0.03) | 0.04 (0.02) | 0.06 (0.02) |
| C20:4n-6 | | 0.08 (0.00) | 0.19 (0.01) | 0.28 (0.03) | 0.33 (0.04) | 0.39 (0.05) |
| n-3 PUFA | | | | | | |
| C18:3n-3 | 8.46 (0.40) | 4.59 (0.23) | 0.86 (0.04) | 5.92 (0.56) | 3.58 (0.25) | 1.03 (0.21) |
| C20:5n-3 | | | | 0.01 (0.01) | 0.01 (0.01) | 0.01 (0.01) |
| C22:6n-3 | | | | 0.07 (0.02) | 0.07 (0.02) | 0.07 (0.02) |

32 Values are presented as means (SD). The fatty acid compositions of three oils were determined by
33 gas chromatograph (Agilent 7820A). The fatty acid compositions of three diets were calculated by
34 the Nutrition System of Traditional Chinese Medicine Combining with Western Medicine Version
35 11.0 (Medical College, Qingdao University, Shandong, China) from dietary intake of 7
36 consecutive days. SFA, saturated fatty acid; MUFA, monounsaturated fatty acid; PUFA,
37 polyunsaturated fatty acid.

38 Table S2. The compositions of the three oils used in the study

| Components | Soybean oil | Blend oil | Lard |
|---------------------------------|--------------|---|---|
| Sterols (mg/100 g) | | | |
| β-sitosterol | 167.3 (30.6) | 76.6 (12.0) | ND |
| Campesterol | 65.0 (6.0) | 31.6 (1.1) | ND |
| Stigmasterol | 60.0 (13.7) | 28.6 (2.0) | ND |
| Cholesterol | ND | 49.2 (4.6) | 102.2 (11.9) |
| | | | |
| Fat soluble vitamins (mg/100 g) | | | |
| vitamin D | ND | 1.4×10^{-3} (0.3×10^{-3}) | 2.3×10^{-3} (0.6×10^{-3}) |
| Tocopherol, alpha | 13.2 (2.6) | 7.0 (1.5) | 0.7 (0.3) |
| Tocopherol, gamma | 69.5 (6.5) | 37.7 (6.4) | ND |
| Tocopherol, delta | 20.6 (3.2) | 13.4 (2.5) | ND |

39 Values are presented as means (SD). ND, not detected.

40 Table S3. The baseline blood pressure of completed the study and dropout subjects

| Groups | Baseline SBP | | | Baseline DBP | | |
|-------------------|---------------------------------|---------------------|------------------|---------------------------------|---------------------|------------------|
| | Subjects completed the study | Dropout subjects | <i>P</i> -Value* | Subjects completed the study | Dropout subjects | <i>P</i> -Value* |
| Soybean oil group | 115.5 (12.9) | 115.5 (9.7) | 0.989 | 75.2 (8.6) | 72.0 (8.1) | 0.123 |
| Blend oil group | 116.8 (12.3) | 117.1 (16.6) | 0.904 | 76.0 (8.9) | 74.7 (12.6) | 0.527 |
| Lard group | 115.4 (9.8) | 115.2 (8.2) | 0.910 | 73.7 (8.3) | 74.5 (7.3) | 0.625 |

41 All values are means (SD). *The two tailed paired *t*-test was used for comparing the differences in
 42 blood pressure between completed the study and dropout subjects at the baseline. SBP, systolic
 43 blood pressure; DBP, diastolic blood pressure.

44 Table S4. Protocol for screening and randomization

| |
|---|
| Advertising |
| Screening visit 1 by face-to-face or telephone or internet interview* |
| Major eligibility questions |
| Health questionnaire |
| Assessment of the tolerance to lard |
| Screening visit 2 by face-to-face or non-face-to-face interview† |
| Collection of basic personal information |
| Sign the informed consent form |
| 3-day dietary records |
| Screening visit 3‡ |
| Weight, height, waist circumferences, blood pressure |
| Overnight fasting blood for eligibility testing |
| Randomization was 12 days after the advertising |

45 *The screening visit 1 was 2 days after the advertising. †The screening visit 2 was 7 days after the
46 advertising. All potential subjects were asked to provide information about their basic personal
47 information and 3-day dietary records and sign the informed consent form. ‡The screening visit 3
48 was 10 days after the advertising. Since participants were subjects working and living in PLA
49 General Hospital, meaning all participants ate the same cooking oil (soybean oil) before the
50 present study. Meanwhile, the cooking oils in the present study were commonly used in China,
51 therefore no run-in period was included.

52 Table S5. Intention-to-treat and per-protocol analysis of blood pressure changes from baseline

| Variable | Week | Soybean oil group | Blend oil group | Lard group | <i>P</i> -Value* | | |
|----------------------|------|--------------------------------|--------------------------------|--------------------------------|------------------|---------|--------------|
| | | | | | Time | Group | Time × group |
| ITT (n = 334) | | | | | | | |
| SBP (mm Hg) | 0 | 115.5 (113.2, 117.8) | 116.9 (114.3, 119.5) | 115.3 (113.6, 117.1) | < 0.001 | 0.001 | 0.023 |
| | Δ4 | -2.1 (-4.3, 0.1) | -3.8 (-5.6, -2.0) | -1.5 (-3.7, 0.7) | | | |
| | Δ8 | -3.6 (-6.1, -1.1) | -6.9 (-9.3, -4.5) ^a | -3.1 (-5.5, -0.7) ^b | | | |
| | Δ12 | -3.3 (-5.7, -0.9) | -6.0 (-8.6, -3.4) ^a | -1.2 (-3.7, 1.4) ^b | | | |
| DBP (mm Hg) | 0 | 74.6 (73.0, 76.2) | 75.6 (73.7, 77.5) | 74.0 (72.5, 75.5) | < 0.001 | 0.001 | 0.008 |
| | Δ4 | -1.4 (-3.2, 0.3) ^a | -4.2 (-5.8, -2.6) ^b | -0.4 (-2.6, 1.7) ^a | | | |
| | Δ8 | -2.4 (-3.9, -0.9) | -4.5 (-6.3, -2.6) ^a | -1.1 (-3.1, 0.9) ^b | | | |
| | Δ12 | 1.5 (-1.0, 4.0) | 0.8 (-1.7, 3.2) | 3.3 (0.9, 5.8) | | | |
| PP (n = 245) | | | | | | | |
| SBP (mm Hg) | 0 | 115.5 (112.8, 118.2) | 116.8 (114.0, 119.6) | 115.4 (113.2, 117.6) | < 0.001 | < 0.001 | 0.006 |
| | Δ4 | -1.5 (-3.8, 0.9) | -3.5 (-5.4, -1.5) | -0.8 (-3.2, 1.6) | | | |
| | Δ8 | -3.3 (-5.9, -0.8) ^a | -7.4 (-9.8, -5.1) ^b | -2.6 (-5.1, -0.2) ^a | | | |
| | Δ12 | -3.1 (-5.5, -0.7) | -6.0 (-8.6, -3.4) ^a | -1.2 (-3.8, 1.4) ^b | | | |
| DBP (mm Hg) | 0 | 75.2 (73.4, 77.0) | 76.0 (74.0, 78.0) | 73.7 (71.8, 75.6) | < 0.001 | < 0.001 | < 0.001 |
| | Δ4 | -1.8 (-3.7, 0.2) | -4.5 (-6.3, -2.7) ^a | 0.6 (-1.8, 3.1) ^b | | | |
| | Δ8 | -2.4 (-4.0, -0.8) ^a | -5.2 (-7.2, -3.2) ^b | 0.2 (-1.8, 2.3) ^c | | | |
| | Δ12 | 1.6 (-0.9, 4.1) | 0.8 (-1.7, 3.2) | 3.4 (0.9, 5.8) | | | |

53 All values are means (95% CIs). *Data are based on mixed-model analysis of variance; changes
54 from baseline were calculated by subtracting 4-, 8-, and 12-week data from baseline data. ITT,
55 intention-to-treat; PP, per-protocol; BP, blood pressure; SBP, systolic blood pressure; DBP,
56 diastolic blood pressure. ^{a,b,c}Different superscripts indicate significant differences between groups.
57 No superscript means no difference compared with any other group; Δ, change from baseline.

58 Table S6. Subgroup analysis of blood pressure in the intention-to-treat participants among three
59 groups

| Variable | Week | Soybean oil group | Blend oil group | Lard group | P-Value* | | |
|------------------------|------|---------------------------------|----------------------------------|--------------------------------|----------|---------|--------------|
| | | | | | Time | Group | Time × group |
| BP: ≥ 130/80 | | | | | | | |
| SBP (n = 9-18) | 0 | 135.8 (130.9, 140.7) | 138.7 (134.0, 143.5) | 131.3 (128.8, 133.9) | < 0.001 | < 0.001 | 0.001 |
| | Δ4 | -3.4 (-11.7, 5.0) | -7.6 (-12.8, -2.4) ^a | 2.2 (-5.6, 10.0) ^b | | | |
| | Δ8 | -6.6 (-12.7, -0.5) ^a | -11.1 (-18.1, -4.1) ^a | 5.4 (-5.6, 16.3) ^b | | | |
| | Δ12 | -7.0 (-11.3, -2.7) | -12.8 (-20.2, -5.5) ^a | 1.4 (-6.9, 9.7) ^b | | | |
| DBP (n = 9-18) | 0 | 87.6 (84.4, 90.7) | 91.8 (87.1, 96.4) | 88.3 (84.5, 92.2) | 0.008 | < 0.001 | 0.005 |
| | Δ4 | -2.2 (-8.0, 3.6) ^a | -10.0 (-14.1, -5.9) ^b | -1.3 (-11.4, 8.8) ^a | | | |
| | Δ8 | -3.9 (-9.7, 1.8) | -8.5 (-14.3, -2.6) ^a | 1.9 (-4.4, 8.2) ^b | | | |
| | Δ12 | 1.8 (-5.0, 8.6) | -6.2 (-13.1, 0.6) ^a | 6.5 (-2.7, 15.7) ^b | | | |
| BP: < 130/80 | | | | | | | |
| SBP (n = 93-101) | 0 | 112.6 (110.7, 114.6) | 112.7 (110.7, 114.7) | 113.9 (112.3, 115.5) | < 0.001 | 0.074 | 0.429 |
| | Δ4 | -1.9 (-4.1, 0.4) | -3.0 (-4.9, -1.1) | -1.9 (-4.2, 0.4) | | | |
| | Δ8 | -3.2 (-5.9, -0.4) | -6.1 (-8.7, -3.6) | -4.0 (-6.4, -1.6) | | | |
| | Δ12 | -2.6 (-5.4, 0.1) | -4.6 (-7.3, -1.9) | -1.5 (-4.2, 1.3) | | | |
| DBP (n = 93-101) | 0 | 72.7 (71.3, 74.2) | 72.5 (71.1, 73.8) | 72.7 (71.3, 74.1) | < 0.001 | 0.096 | 0.270 |
| | Δ4 | -1.3 (-3.2, 0.6) | -3.0 (-4.7, -1.3) | -0.3 (-2.5, 1.9) | | | |
| | Δ8 | -2.1 (-3.7, -0.6) | -3.7 (-5.7, -1.8) | -1.4 (-3.5, 0.8) | | | |
| | Δ12 | 1.5 (-1.3, 4.2) | 2.2 (-0.3, 4.7) | 3.0 (0.4, 5.5) | | | |
| BMI: ≥ 25 | | | | | | | |
| SBP (n = 39-44) | 0 | 122.0 (118.2, 125.8) | 121.4 (116.7, 126.2) | 120.1 (117.4, 122.8) | < 0.001 | 0.002 | 0.012 |
| | Δ4 | -2.6 (-7.0, 1.9) | -4.1 (-7.3, -1.0) | -0.1 (-3.4, 3.3) | | | |
| | Δ8 | -6.0 (-10.6, -1.4) | -4.9 (-10.0, 0.1) | -1.9 (-6.0, 2.2) | | | |
| | Δ12 | -5.3 (-8.9, -1.8) ^a | -7.9 (-13.3, -2.5) ^a | 1.8 (-1.8, 5.4) ^b | | | |
| DBP (n = 39-44) | 0 | 79.4 (76.8, 82.0) | 80.0 (76.9, 83.2) | 78.2 (76.2, 80.3) | < 0.001 | < 0.001 | 0.002 |
| | Δ4 | -2.2 (-5.2, 0.9) | -6.2 (-9.1, -3.3) ^a | 0.1 (-3.3, 3.4) ^b | | | |
| | Δ8 | -4.1 (-6.8, -1.5) | -5.7 (-9.0, -2.4) ^a | -0.4 (-3.7, 3.0) ^b | | | |
| | Δ12 | 1.3 (-2.4, 4.9) | -1.5 (-5.7, 2.6) ^a | 4.5 (1.5, 7.5) ^a | | | |
| BMI: < 25 | | | | | | | |
| SBP (n = 66-74) | 0 | 112.1 (109.4, 114.7) | 114.2 (111.3, 117.0) | 112.2 (110.2, 114.2) | < 0.001 | 0.012 | 0.086 |
| | Δ4 | -1.8 (-4.3, 0.7) | -3.6 (-5.8, -1.3) | -2.6 (-5.5, 0.4) | | | |
| | Δ8 | -2.3 (-5.3, 0.7) ^a | -8.0 (-10.5, -5.5) ^b | -3.9 (-6.9, -1.0) ^a | | | |
| | Δ12 | -2.1 (-5.4, 1.1) | -4.9 (-7.7, -2.1) | -3.4 (-6.8, 0.1) | | | |
| DBP (n = 66-74) | 0 | 72.0 (70.3, 73.8) | 72.9 (70.7, 75.1) | 71.1 (69.3, 73.0) | < 0.001 | 0.326 | 0.572 |
| | Δ4 | -1.0 (-3.2, 1.2) | -2.9 (-4.8, -1.0) | -0.8 (-3.7, 2.1) | | | |
| | Δ8 | -1.4 (-3.3, 0.5) | -3.8 (-6.0, -1.5) | -1.6 (-4.1, 1.0) | | | |
| | Δ12 | 1.7 (-1.7, 5.1) | 2.1 (-1.0, 5.1) | 2.5 (-1.2, 6.1) | | | |
| Age: ≥ 45 | | | | | | | |

| | | | | | | | |
|-----------------------|-----|--------------------------------|----------------------------------|-------------------------------|---------|---------|-------|
| SBP (n = 21-33) | 0 | 121.9 (116.7, 127.1) | 127.6 (121.1, 134.1) | 121.1 (117.7, 124.5) | < 0.001 | 0.043 | 0.146 |
| | Δ4 | -3.3 (-8.5, 1.9) | -2.1 (-6.2, 2.0) | 0.6 (-6.1, 7.3) | | | |
| | Δ8 | -4.4 (-9.1, 0.4) | -7.7 (-14.0, -1.4) | -2.8 (-9.3, 3.6) | | | |
| | Δ12 | -4.9 (-8.9, -0.9) ^a | -12.3 (-19.9, -4.8) ^b | -0.9 (-7.8, 5.9) ^a | | | |
| DBP (n = 21-33) | 0 | 77.7 (74.5, 80.9) | 82.9 (76.8, 88.9) | 79.3 (76.5, 82.0) | 0.037 | 0.246 | 0.739 |
| | Δ4 | -2.2 (-6.1, 1.7) | -5.2 (-8.9, -1.5) | -1.1 (-5.3, 3.1) | | | |
| | Δ8 | -1.9 (-4.7, 1.0) | -2.9 (-8.8, 2.9) | -1.4 (-6.7, 3.8) | | | |
| | Δ12 | 2.8 (-1.1, 6.7) | -1.7 (-10.1, 6.7) | 1.3 (-3.1, 5.7) | | | |
| Age: < 45 | | | | | | | |
| SBP (n = 80-90) | 0 | 112.9 (110.6, 115.1) | 114.4 (111.8, 117.0) | 113.7 (111.8, 115.7) | < 0.001 | 0.008 | 0.107 |
| | Δ4 | -1.5 (-3.8, 0.7) | -4.1 (-6.2, -2.1) | -2.1 (-4.3, 0.1) | | | |
| | Δ8 | -3.3 (-6.3, -0.3) | -6.7 (-9.3, -4.0) | -3.2 (-5.8, -0.6) | | | |
| | Δ12 | -2.5 (-5.6, 0.6) | -4.5 (-7.1, -1.8) | -1.2 (-4.0, 1.5) | | | |
| DBP (n = 80-90) | 0 | 73.3 (71.5, 75.1) | 73.9 (72.1, 75.7) | 72.5 (70.8, 74.2) | < 0.001 | 0.002 | 0.009 |
| | Δ4 | -1.1 (-3.0, 0.8) | -4.0 (-5.9, -2.1) | -0.2 (-2.8, 2.3) | | | |
| | Δ8 | -2.6 (-4.5, -0.8) | -4.8 (-6.7, -2.9) | -1.0 (-3.2, 1.2) | | | |
| | Δ12 | 0.9 (-2.4, 4.1) ^a | 1.4 (-1.0, 3.7) ^a | 3.9 (1.0, 6.7) ^b | | | |
| Gender: male | | | | | | | |
| SBP (n = 40-50) | 0 | 122.7 (119.3, 126.2) | 123.8 (120.5, 127.1) | 119.8 (117.5, 122.1) | < 0.001 | < 0.001 | 0.001 |
| | Δ4 | -0.7 (-3.9, 2.5) | -3.4 (-5.9, -0.8) | 0.6 (-3.5, 4.7) | | | |
| | Δ8 | -3.3 (-6.9, 0.3) | -7.6 (-10.7, -4.4) ^a | -1.3 (-5.8, 3.2) ^b | | | |
| | Δ12 | -2.9 (-6.9, 1.1) ^a | -7.3 (-10.5, -4.2) ^a | 2.6 (-1.5, 6.6) ^b | | | |
| DBP (n = 40-50) | 0 | 79.6 (77.2, 82.0) | 79.4 (76.3, 82.5) | 76.8 (74.5, 79.2) | < 0.001 | 0.002 | 0.034 |
| | Δ4 | -0.7 (-3.7, 2.2) | -2.4 (-5.0, 0.1) | 1.8 (-1.8, 5.4) | | | |
| | Δ8 | -1.1 (-3.6, 1.4) | -3.1 (-5.7, -0.6) ^a | 1.1 (-2.5, 4.7) ^b | | | |
| | Δ12 | 2.6 (-1.3, 6.6) ^a | 2.4 (-1.3, 6.2) ^a | 8.1 (5.0, 11.1) ^b | | | |
| Gender: female | | | | | | | |
| SBP (n = 61-70) | 0 | 110.9 (108.3, 113.4) | 111.3 (108.0, 114.5) | 112.8 (110.6, 115.0) | < 0.001 | 0.327 | 0.878 |
| | Δ4 | -3.0 (-6.0, 0.1) | -4.1 (-6.7, -1.5) | -2.7 (-5.3, -0.2) | | | |
| | Δ8 | -3.9 (-7.3, -0.4) | -6.4 (-9.9, -2.8) | -4.2 (-7.0, -1.4) | | | |
| | Δ12 | -3.6 (-6.7, -0.4) | -4.9 (-8.9, -0.8) | -3.1 (-6.3, 0.0) | | | |
| DBP (n = 61-70) | 0 | 71.4 (69.6, 73.1) | 72.5 (70.4, 74.6) | 72.3 (70.4, 74.2) | < 0.001 | 0.027 | 0.112 |
| | Δ4 | -1.8 (-4.1, 0.4) ^a | -5.5 (-7.6, -3.3) ^b | -1.7 (-4.4, 1.0) ^a | | | |
| | Δ8 | -3.2 (-5.2, -1.2) | -5.5 (-8.1, -2.9) | -2.3 (-4.7, 0.1) | | | |
| | Δ12 | 0.8 (-2.5, 4.1) | -0.6 (-3.8, 2.6) | 0.8 (-2.4, 4.0) | | | |

60 Values are presented as means (95% CIs). *Comparisons among three groups were performed
61 using mixed-model analysis of variance; changes from baseline were calculated by subtracting 4-,
62 8-, and 12-week data from baseline data. BP, blood pressure; SBP, systolic blood pressure; DBP,
63 diastolic blood pressure; BMI, body mass index. ^{a,b}Different superscripts indicate significant

- 64 differences between groups. No superscript means no difference compared with any other group;
- 65 Δ , change from baseline.